Paul Ashton

Company: Inflammasome Therapeutics

Job title: Chief Executive Officer

Seminars:

Fireside Chat: What Each Stakeholder Needs – Repositioning Inflammasome Therapies for Clinical, Commercial & Capital Success 3:45 pm

Exploring the rationale for advancing multiple inflammasome-targeting programs in parallel while managing clinical risk through indication diversity Outlining key regulatory requirements for inflammasome-targeting therapeutics (safety pharmacology, dosing windows, and MOA validation) Shedding light on how successful Phase II data influences Series B/C financing rounds, partnerships, and acquisition strategiesRead more

day: Conference Day One PM

Overcoming Species-Specific Limitations in Preclinical Models for Human Disease 9:01 am

One of the greatest challenges in developing inflammasome-targeted therapies is the lack of preclinical models that accurately reflect the complexity of human inflammasome biology. Murine models, while widely used, often fail to capture key species-specific differences in the multi-protein complex components such as NLRP1 and CARD8, as well as the differential regulation of caspases and…Read more

day: Pre-Conference Workshop Day